# Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma

> **NCT05925413** · PHASE2 · UNKNOWN · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cadonilimab+TACE

## Key facts

- **NCT ID:** NCT05925413
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-24
- **Primary completion:** 2024-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05925413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05925413, "Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05925413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*